PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
Ann Rheum Dis. 2007 May; 66(5): 599–604.
Published online 2006 November 17. doi:  10.1136/ard.2006.061945
PMCID: PMC1954639

T cell responses to a non‐glycosylated epitope predominate in type II collagen‐immunised HLA‐DRB1*0101 transgenic mice

Abstract

Aim

To study collagen‐induced arthritis in human leucocyte antigen (HLA)‐DR1 transgenic mice lacking endogenous major histocompatibility complex class II molecules (MHC‐II) and to determine T cell specificity against the arthritogenic CII259–273 epitope of type II collagen either unmodified or post‐translationally glycosylated at Lys264.

Methods

Arthritis was induced by immunisation with human type II collagen in complete Freund's adjuvant and measured by footpad swelling, clinical score and histology. T cell responses were assessed by proliferation of spleen and lymph node cells and in antigen presentation assays, using T cell hybridomas specific for the glycosylated and non‐glycosylated CII259–273 epitope.

Results

The incidence of arthritis was 50% in DR1‐transgenic mice lacking endogenous MHC‐II molecules. Recall T cell responses in draining lymph nodes and spleen were consistently greater against the non‐glycosylated epitope than to the glycosylated CII259–273. Most of the T cell hybridomas generated from CII‐immunised mice recognised the non‐glycosylated CII epitope and this form of the epitope was also presented with 100‐fold higher efficiency and 1 h faster kinetics by both macrophages and dendritic cells.

Conclusion

This study shows that T cell responses to the non‐glycosylated epitope of heterologous (human) CII are dominant in HLA‐DR1 transgenic mice lacking MHC‐II, which could contribute to the pathogenicity of autoimmune arthritis.

The contribution of human leucocyte antigen (HLA)‐DRB1 alleles to the pathogenesis of rheumatoid arthritis (RA) is estimated as 40%.1 In particular, the expression of HLA‐DR4 (HLA‐DRB1*0401) and HLA‐DR1 (HLA‐DRB1*0101) has been shown to predispose to RA.2,3,4,5 HLA‐DRB1*0401 is associated with severe erosive RA, whereas expression of HLA‐DRB1*0101 is associated with less severe non‐erosive disease.5,6,7

The primary structure of the peptide‐binding pocket of mouse major histocompatibility complex class II (MHC‐II) Aq molecules has been shown to be very similar to that of HLA‐DRB1*0401 and HLA‐DRB1*01018 and expression of Aq confers susceptibility to collagen‐induced arthritis (CIA).9,10 Mice expressing non‐susceptible MHC haplotypes (ie, not H‐2q or H‐2r,11) that express HLA‐DRB1*0401 or HLA‐DRB1*0101 also acquire susceptibility to CIA12,13,14 but it is not known whether the endogenous mouse MHC class molecules contribute in anyway to the induction or severity of arthritis.

T cells from type II collagen (CII)‐immunised HLA‐DRB1*0401 and HLA‐DRB1*0101 mice predominantly recognise the same immunodominant CII259–273 epitope.11,12,13,15,16 In HLA‐DRB1*0401 CD4 double transgenic mice lacking MHC‐II, the T cells recognised many different forms of the peptides including the glycosylation of the Lys264 residue within the CII259–273 epitope.17,18,19 Interestingly, when these mice expressed humanised CII the response to the glycosylated structure was relatively stronger indicating a less well‐developed tolerance to post‐translationally modified CII epitopes.14,17

Methods

Antigens

Human CII was purchased from MD BioSciences (Zürich, Switzerland). The glycosylated peptide (GIAGFKGEQGPKGET; K = GalHyL264) corresponding to epitope CII259–273 was synthesised.20 The non‐glycosylated peptide pCII259–273 was purchased from GenScript Corp (Piscataway, New Jersey, USA).

Animals

Transgenic (tg) mice carried full‐length genomic constructs for HLA‐DRA1*0101 and HLA‐DRB1*010121 and were crossed for more than six generations to C57BL/6 Ab null mice.22 Breeding founders were genotyped by PCR for the presence of the HLA transgenes and HLA‐DR expression was monitored by flow cytometry.23,24 The proportion of T cells, B cells, macrophages and dendritic cells as well as the level of expression of MHC II molecules (HLA‐DR1 compared with Ab) and T cell receptor (TCR) Vβ family distribution were comparable between HLA‐DR1‐tg mice and C57BL/6, the background mouse strain (data not shown). The work was approved by the ethics committee of the Newcastle University.

Collagen‐induced arthritis

CIA was induced by immunisation at the base of the tail with 100 µg human CII in complete Freund's adjuvant (CFA, Chondrex, Washington, USA). The same dose of CII in incomplete Freund's adjuvant (IFA) was given 3 weeks later. The severity of CIA was monitored as the thickness of the hind paws using an Oditest dial caliper gauge (reading error of 0.01 mm, Kroeplin GmbH, Schüchtern, Germany). Clinical scoring was performed using an established scoring system: 0 = normal joints, 1 = 1 or 2 swollen joints, 2 = >2 swollen joints and 3 = extreme swelling of the entire paw and/or ankylosis.12

Cells

Culture media ingredients were from Sigma Chemical Co (Dorset, UK). Cells were grown in culture medium (RPMI 1640 medium containing 3 mM L‐glutamine, 50 μM 2‐mercaptoethanol, 10% fetal bovine serum and 30 μg/ml gentamycin). T cell hybridomas were generated by polyethylene–glycol fusion of BW5147 (TCRα‐β‐) cells with T cell lines from CII‐immunised mice after six rounds of restimulation. Macrophages (purity ~95% based on CD11b expression) were grown from femoral bone marrow cells in culture medium containing L929 supernatant as a source of macrophage colony stimulating factor (M‐CSF).23 Macrophages were activated with 10 U/ml recombinant IFNγ (R&D Systems, Abingdon, UK) for 24 h.23 Bone marrow dendritic cells (DC, purity ~92% based on CD11c expression) were grown in culture medium containing 20 ng/ml recombinant mouse granulocyte–macrophage colony stimulating factor (GM‐CSF, BioSource International, Nivelles, Belgium). DC were purified using anti‐CD11c‐coated magnetic microbeads (Miltenyi Biotec, Bisley, UK) and maturation was induced by 0.2 µg/ml lipopolysaccharide for 24 h.24

Proliferation assays

CII‐specific T cell proliferation responses were measured in popliteal lymph nodes removed 7 days after immunisation with 50 µg CII emulsified 1:1 in TiterMax adjuvant (Sigma Chemical Co) or phosphate‐buffered saline (PBS)/TiterMax. Responses of spleen cells were measured in mice with CIA. Cells (2×105/well) were mixed with antigens or the polyclonal T cell mitogen concanavalin A (5.0 µg/ml) and incubated for 4 days, including 14.8 kBq of [3H]‐thymidine for the past 18 h and radioactivity was measured as described below.

Antigen presentation assays

Adherent macrophages at 105/well or DC at 104/well were pulsed with a dilution series of CII or synthetic peptides, fixed with 1.0% paraformaldehyde, and T cell hybridoma HCII‐9.1 ((CD3+ TCRαβ+ Vβ14+) specific for the non‐glycosylated peptide) or HCII‐9.2 ((CD3+ TCRαβ+ Vβ8.1/8.2+) specific for the glycosylated peptide) were added (5×104/well) and incubated for 24 h at 37°C.23 Responses to synthetic peptides were used as a positive control for T cell hybridomas. The interleukin (IL)2 content of hybridoma supernatants was measured as proliferation of the cytotoxic T cell line 2 (CTLL‐2, 3×104/well, American Type Culture Collection ATCC, TIB 214, Rockville, Maryland, USA) incubated for 18 h in the presence of 14.8 kBq of [3H]thymidine (TRA310, specific activity 307 MBq/mg; Amersham International plc, Didcot, UK). Cells were harvested on glass fibre membranes and radioactivity was quantitated using a direct beta counter (Matrix 9600, Packard Instrument Company, Meridan, Connecticut, USA). To measure non‐specific, polyclonal responses of T cell hybridomas, a dilution series of rat anti‐CD3 antibodies (clone KT3, generous gift of Dr CG Brooks, Newcastle University) were coated on 96 well plates, and T cell hybridoma were added and assayed as above.

Histology

Arthritic and non‐arthritic paws were removed and fixed in 7% formaldehyde pH 7.4, decalcified in 14% EDTA pH 7.4, and embedded in paraffin wax. Serial sections (5 µm) of the joints were stained with H&E and examined as blinded samples at the Department of Cellular Pathology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.

Flow cytometry

Cells were incubated for 30 min at 4°C in Hank's balanced salt solution containing 2% fetal bovine serum, 0.01 M N‐2‐hydroxyethylpiperazine‐N′‐2‐ethanesulfonic acid with purified anti‐mouse CD16/CD32 (Fc Block, BD‐PharMingen, Oxford, UK) followed by incubation for 30 min at 4°C with either of the following mAb fluorescent conjugates (BD‐PharMingen) specific for: TCRαβ/phycoerythrin (PE), HLA‐DR/fluorescein isothiocyanate (FITC) or HLA‐DR/PE, CD11c/FITC, CD11b/FITC, CD19/PE, CD4/FITC, CD8/FITC, I‐Ab/FITC or rat IgG2a/PE plus IgG2b/FITC as isotype controls. The TCR Vβ family distribution in the spleen was studied using a panel of FITC‐conjugated mAb to mouse TCR Vβ chains (BD‐PharMingen).25 Cells were analysed with by flow cytometry (Becton Dickinson FACScan, Mount View, California, USA) and 10 000 events were collected and analysed for each sample using CellQuestPro software.

Statistical analysis

Statistical differences were analysed by two‐way analysis of variance and two‐tailed paired t tests. Analysis of variance Bonferroni post‐tests were used to compare replicate means. The dose of CII that induced 50% T cell hybridoma responses (Effective dose50, ED50) was calculated according to the sigmoidal or bottom‐to‐top curve fitting models (Prism 4.03 and GraphPad StatMate 1.00, GraphPad Software Inc, San Diego, USA).

Results

Development of collagen‐induced arthritis

We induced CIA in HLA‐DR1‐tg mice lacking MHC‐II by a single subcutaneous immunisation with 100 µg CII emulsified in CFA. In some experiments CII/CFA immunisation was followed by boosting with CII/IFA. Arthritis was observed 30 days after immunisation independently of the immunisation protocol, evidenced by the increase in hind paw thickness and clinical score compared with mice immunised with PBS/CFA (fig 1A,B1A,B).). The severity of arthritis peaked 45 days after immunisation (fig 1A,B1A,B)) corresponding to the maximum incidence of 50% (fig 1C1C).

figure ar61945.f1
Figure 1 Clinical scoring of collagen‐induced arthritis (CIA). CIA was induced by single immunisation with type II collagen (CII)/ complete Freund's adjuvant (CFA; filled squares) or followed by a second immunisation with CII/IFA 3 weeks ...

Macroscopically both hind and fore paws developed oedema and redness with pronounced loss of function compared with PBS/CFA‐immunised mice (fig 22).). Histological examination revealed cartilage loss, synovial inflammation and bone destruction of all small joints inspected from representative hind‐paws of three mice with CIA compared with control mice (fig 22).). The data showed that mice were susceptible to CIA with clinical and histological features characteristic of RA.

figure ar61945.f2
Figure 2 Appearance of collagen‐induced arthritis (CIA). Mice with CIA (A) but not untreated mice (B) displayed extensive rubor and oedema around metacarpophalangeal and interphalangeal joints (top two panels) and metatarsophalangeal and ...

Specificity of T cell responses

We studied the effect of CII259–273 glycosylation on T cell specificity after CII/CFA immunisation. Sixty days after CII/CFA immunisation, CII‐specific spleen T cell responses were detected only in arthritic mice (fig 3A,B3A,B).). These T cell responses showed a bias towards specificity for the non‐glycosylated, as compared with the glycosylated, CII259–273 epitope (p<0.001; fig 3A3A).). Mice were also foot‐pad immunised with CII/TiterMax before popliteal lymph node assays 7 days later. T cell proliferation was again biased to recognition of the non‐glycosylated epitope in addition to a response to intact CII (p<0.001; fig 3C3C).).

figure ar61945.f4
Figure 3 Type II collagen (CII)‐specific T cell responses. Proliferation responses of spleen cells of mice immunised with CII/CFA with arthritis (A) or without arthritis (B) to CII (squares), non‐glycosylated (circles) or glycosylated ...

Specificity of T cell hybridoma responses

We generated a panel of 44 CII‐specific T cell hybridomas from six mice and assayed responses to the glycosylated and non‐glycosylated CII259–273 in an antigen presentation assay. Most CII‐specific T cell hybridomas (42/44, 95.5%) recognised the non‐glycosylated CII259–273 epitope, and only two T cell hybridomas recognised the glycosylated epitope (fig 3D3D).). Altogether, our data showed that immunisation of HLA‐DR1‐tg mice resulted in a predominant response to the non‐glycosylated CII259–273 epitope.

We addressed whether differences in processing and presentation of CII in professional antigen presenting cells (APCs) accounted for the observed expansion of CD4 T cells specific for the non‐glycosylated CII259–273 epitope. We assayed antigen presentation of the glycosylated and non‐glycosylated CII259–273 epitope from soluble CII by DC and macrophages using two T cell hybridomas with similar TCR affinities judged from dose‐response titrations to synthetic peptides and anti‐CD3 antibodies (fig 44),), and levels of TCR expression by flow cytometry (data not shown). The requirement for proteolytic processing of soluble CII for presentation of the glycosylated and non‐glycosylated CII259–273 was reported previously.23 Presentation of the glycosylated, as compared with the non‐glycosylated epitope, was characterised by significantly lower efficiency in both macrophages (100‐fold difference) and DC (200‐fold difference; fig 5A,B5A,B).). Similarly, significantly delayed kinetics (by approximately 1 h) of antigen presentation was characteristic of the glycosylated, as compared with the non‐glycosylated epitope, in macrophages and in DC (fig 5C,D5C,D).). The data showed that CII was more efficiently processed by professional APCs for presentation of the non‐glycosylated, compared with the glycosylated epitope. This apparent immunodominance of the non‐glycosylated CII259–273 in antigen presentation experiments in vitro is consistent with expansion of polyclonal T cells against this form of the epitope in HLA‐DR1‐tg mice in vivo, shown in fig 33.

figure ar61945.f3
Figure 4 Dose‐response titrations of T cell hybridomas. Responses of T cell hybridoma HCII‐9.1 (closed symbols, non‐glycosylated epitope) or HCII‐9.2 (open symbols, glycosylated epitope) to a dose range of synthetic ...
figure ar61945.f5
Figure 5 Antigen presentation. Macrophages (A) or DC (B) were pulsed with CII for 5 h. Macrophages (C) or DC (D) were pulsed with CII for different periods of time. Responses of T cell hybridoma HCII‐9.1 (closed symbols, non‐glycosylated ...

Discussion

We studied the development of CIA after CII immunisation in HLA‐DR1‐tg mice lacking MHC‐II. In this study, a high severity of CIA was observed with the incidence rate of approximately 50%. By contrast, HLA‐DR1‐tg(H2f) mice and HLA‐DR4‐tg mice lacking MHC‐II were reported to be highly susceptible to CIA with 88–100% incidence rate.12,14 Previous population studies in patients with RA showed that different HLA‐DRB1 alleles influence the severity of RA with HLA‐DRB1*0401 being associated with severe, seropositive, erosive RA, whereas DRB1*0101 with less severe, seronegative, non‐erosive disease.5,6,7 Further studies will shed light on the reasons for the reduced incidence rate (but not the severity) of CIA in HLA‐DR1‐tg mice lacking MHC‐II.

CII‐specific T cells in HLA‐DR4‐tg mice were shown to recognise predominantly the non‐glycosylated CII259‐273, but the response was skewed towards recognition of the glycosylated form when the human CII was transgenically expressed.17,18,19 We studied T cell responses in draining lymph nodes and spleen of HLA‐DR1‐tg mice after CII immunisation and showed a bias towards T cell responses specific for the non‐glycosylated in preference to the glycosylated CII259–273 epitope. This conclusion was confirmed by producing a panel of CII‐specific T cell hybridomas, most of which recognised the non‐glycosylated epitope. We addressed whether the APC type determined the predominance of T cells specific for the non‐glycosylated CII259–273 by studying antigen presentation of both forms of CII259–273 to T cells by macrophages and DC, which have been previously shown to be the major APC involved in CII presentation.23,26,27 Presentation of the glycosylated CII259–273 was characterised by more than 100‐fold lower efficiency and occurred with about 1 h slower kinetics, as compared with the non‐glycosylated epitope independent of the APC type. Hence, high efficiency of antigen presentation of the non‐glycosylated CII259–273 could account for the predominant specificity of peripheral T cells against the non‐glycosylated epitope. Low efficiency of antigen presentation of the glycosylated CII259–273 could potentially reflect its lower affinity for HLA‐DR1, as glycosylation was shown previously to decrease CII peptide affinity for Aq molecules.28

According to our unpublished data, adoptive transfer of the T cell hybridoma HCII‐9.1 specific for the non‐glycosylated CII259–273 epitope, but not the HCII‐9.2 specific for the glycosylated epitope, induced mild synovial inflammation in small interphalangeal joints. Synovitis in small joints is reported to be a reliable marker for subsequent x ray changes in the same joints in RA,29 suggesting potential arthritogenicity of the non‐glycosylated form of CII259–273 in HLA‐DR1‐tg mice. By contrast, arthritogenic T cell responses in HLA‐DR4CD4‐tg mice lacking MHC‐II had higher responses towards the glycosylated CII259–273 epitope,17 possibly due to the differential processing of CII in HLA‐DR1‐tg and HLA‐DR4/CD4‐tg mice. Our data suggest that post‐translational glycosylation of Lys264 has different consequences for CII‐specific T cell responses restricted by different HLA‐DRB1 alleles that confer susceptibility to RA. We propose that HLA‐DR1 biases response towards the non‐glycosylated epitope, as shown in the present study. It remains to be determined whether the response will be skewed towards recognition of the glycosylated peptide, as observed in the DR4 mice, in a tolerising situation when human CII is expressed.

Our finding is consistent with the presence of T cells specific for both the glycosylated and non‐glycosylated CII259–273 in peripheral blood of patients with RA.17,30 Coexpression of both HLA‐DR1 and HLA‐DR4 has been shown to increase the risk of developing RA,5 which we propose could be due to the additive effect of two HLA‐DR susceptibility alleles presenting essentially different forms of the CII259–273 epitope. Our study suggests a pathophysiological role for HLA‐DR1‐restricted T cell responses against a non‐glycosylated CII epitope in murine CIA, and shows that HLA‐DR1‐tg mice lacking MHC‐II may be a useful model to study the specificity of T cell responses in RA.

Acknowledgements

We thank Professor Jan Kihlberg, Umeå University, for synthesis of galactosylated peptides and Professor T E Cawston, University of Newcastle, for useful discussions. We thank Dr Colin Brooks, Newcastle University, for anti‐CD3 antibodies. The work was supported by project grant MP/R0619 from the Arthritis Research Campaign, UK.

Abbreviations

APC - antigen presenting cells

CFA - complete Freund's adjuvant

CIA - collagen‐induced arthritis

DC - dendritic cells

FITC - fluorescein isothiocyanate

HLA - human leucocyte antigen

IFA - incomplete Freund's adjuvant

MHC‐II - major histocompatibility complex class‐II

PBS - phosphate‐buffered saline

PE - phycoerythrin

RA - rheumatoid arthritis

TCR - T cell receptor

TG - transgenic

Footnotes

Competing interests: None declared.

References

1. de Vries R R P, Huizinga T W J, Toes R E M. Redefining the HLA and RA association: to be or not to be anti‐CCP positive. Autoimmunity 2005. 2521–25.25
2. Stastny P. Mixed lymphocyte cultures in rheumatoid arthritis. J Clin Invest 1976. 571148–1157.1157 [PMC free article] [PubMed]
3. Corrigall V M, Bodman‐Smith M D, Fife M S, Canas B, Myers L K, Wooley P. et al The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. J Immunol 2001. 1661492–1498.1498 [PubMed]
4. Brownlie R J, Myers L K, Wooley P H, Corrigall V M, Bodman‐Smith M D, Panayi G S. et al Treatment of murine collagen‐induced arthritis by the stress protein BiP via interleukin‐4‐producing regulatory T cells: a novel function for an ancient protein. Arthritis Rheum 2006. 54854–863.863 [PubMed]
5. Zanelli E H, Breedveld F C, de Vries R R P. HLA class II association with rheumatoid arthritis: facts and interpretations. Hum Immunol 2000. 611254–1261.1261 [PubMed]
6. Weyand C M, McCarthy T G, Goronzy J J. Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis. J Clin Invest 1995. 952120–2126.2126 [PMC free article] [PubMed]
7. Harney S M, Newton J L, Wordsworth B P. Molecular genetics of rheumatoid arthritis. Arthritis Rheum 2003. 3280–285.285
8. Holmdahl R, Bockermann R, Bäcklund J, Yamada H. The molecular pathogenesis of collagen‐induced arthritis in mice—a model for rheumatoid arthritis. Ageing Res Rev 2002. 1135–147.147 [PubMed]
9. Brunsberg U, Gustafsson K, Jansson L, Michaëlsson E, Ahrlund‐Richter H, Pettersson S. et al Expression of a transgenic class II Ab gene confers susceptibility to collagen‐induced arthritis. Eur J Immunol 1994. 241698–1702.1702 [PubMed]
10. Myers L K, Rosloniec E F, Cremer M A, Kang A H. Collagen‐induced arthritis, an animal model of autoimmunity. Life Sci 1997. 611861–1878.1878 [PubMed]
11. Holmdahl R. Dissection of the genetic complexity of arthritis using animal models. Immunol Lett 2006. 10386–91.91 [PubMed]
12. Rosloniec E F, Brand D D, Myers L K, Whittington K B, Gumanovskaya M, Zaller D M. et al An HLA‐DR1 transgene confers susceptibility to collagen‐induced arthritis elicited with human type II collagen. J Exp Med 1997. 1851113–1122.1122 [PMC free article] [PubMed]
13. Rosloniec E F, Brand D D, Myers L K, Esaki Y, Whittington K B, Zaller D M. et al Induction of autoimmune arthritis in HLA‐DR4 (DRB1*0401) transgenic mice by immunization with human and bovine type II collagen. J Immunol 1998. 1602573–2578.2578 [PubMed]
14. Andersson E C, Hansen B E, Jacobsen H, Madsen L S, Andersen C B, Engberg J. et al Definition of MHC and T cell receptor contacts in the HLA‐DR4 restricted immunodominant epitope in type II collagen and characterization of collagen‐induced arthritis in HLA‐DR4 and human CD4 transgenic mice. Proc Natl Acad Sci USA 1998. 957574–7579.7579 [PubMed]
15. Fugger L, Rothbard J B, Sonderstrup‐McDevitt G. Specificity of an HLA‐DRB1*0401‐restricted T cell response to type II collagen. Eur J Immunol 1996. 26928–933.933 [PubMed]
16. Rosloniec E F, Whittington K B, Zaller D M, Kang A H. HLA‐DR1 (DRB1*0101) and DR4 (DRB1*0401) use the same anchor residues for binding an immunodominant peptide derived from human type II collagen. J Immunol 2002. 168253–259.259 [PubMed]
17. Bäcklund J, Carlsen S, Hoger T, Holm B, Fugger L, Kihlberg J. et al Predominant selection of T cells specific for the glycosylated collagen type II epitope (263–270) in humanized transgenic mice and in rheumatoid arthritis. Proc Natl Acad Sci USA 2002. 999960–9965.9965 [PubMed]
18. Michaëlsson E, Malmström V, Reis S, Engström Å, Burkhardt H, Holmdahl R. T cell recognition of carbohydrates on type II collagen. J Exp Med 1994. 180745–749.749 [PMC free article] [PubMed]
19. Bäcklund J, Treschow A, Bockermann R, Holm B, Holm L, Issazadeh‐Navikas S. et al Glycosylation of type II collagen is of major importance for T cell tolerance and pathology in collagen‐induced arthritis. Eur J Immunol 2002. 323776–3784.3784 [PubMed]
20. Holm B, Baquer S M, Holm L, Holmdahl R, Kihlberg J. Role of the galactosyl moiety of collagen glycopeptides for T‐cell stimulation in a model for rheumatoid arthritis. Bioorg Med Chem 2003. 113981–3987.3987 [PubMed]
21. Altmann D M, Douek D C, Frater A J, Hetherington C M, Inoko H, Elliott J I. The T cell response of HLA‐DR transgenic mice to human myelin basic protein and other antigens in the presence and absence of human CD4. J Exp Med 1995. 181867–875.875 [PMC free article] [PubMed]
22. Cosgrove D, Gray D, Dierich A, Kaufman J, Lemeur M, Benoist C. et al Mice lacking MHC class II molecules. Cell 1991. 661051–1066.1066 [PubMed]
23. von Delwig A, Altmann D M, Isaacs J D, Harding C V, Holmdahl R, McKie N. et al The impact of glycosylation on HLA‐DR1 restricted T cell recognition of type II collagen in a mouse model. Arthritis Rheum 2006. 54482–491.491 [PubMed]
24. von Delwig A, Hilkens C M U, Altmann D M, Holmdahl R, Isaacs J D, Harding C V. et al Inhibition of macropinocytosis blocks antigen presentation of type II collagen in vitro and in vivo in HLA‐DR1 transgenic mice. Arthritis Res Ther 2006. 8R93
25. Delvig A A, Robinson J H, Wetzler L M. Testing meningococcal vaccines for mitogenicity and superantigenicity. In: Pollard A J, Maiden MC, eds. J Meningococcal vaccines Methods and protocols. 66. Totowa, NJ: Humana Press, 2001. 199–221.221
26. Holmdahl M, Grubb A, Holmdahl R. Cysteine proteases in Langerhans cells limits presentation of cartilage derived type II collagen for autoreactive T cells. Int Immunol 2004. 16717–726.726 [PubMed]
27. Manoury‐Schwartz B, Chiocchia G, Lotteau V, Fournier C. Selective increased presentation of type II collagen by leupeptin. Int Immunol 1997. 9581–589.589 [PubMed]
28. Kjellen P, Brunsberg U, Broddefalk J, Hansen B, Vestberg M, Ivarsson I. et al The structural basis of MHC control of collagen‐induced arthritis; binding of the immunodominant type II collagen 256–270 glycopeptide to H‐2Aq and H‐2Ap molecules. Eur J Immunol 1998. 28755–767.767 [PubMed]
29. Hassell A B, Plant M J, Clarke S, Fisher J, Jones P W, Saklatvala J. et al Small joint synovitis in rheumatoid arthritis: should it be assessed separately? Br J Rheumatol 1995. 3451–55.55 [PubMed]
30. Kim H Y, Kim W U, Cho M L, Lee S K, Joun J, Kim S I. et al Enhanced T cell proliferative response to type II collagen and synthetic peptide CII (255–274) in patients with rheumatoid arthritis. Arthritis Rheum 1999. 422085–2093.2093 [PubMed]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group